Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
This article reviews data on the safety, tolerability, and efficacy of the extended-delivery stimulant preparations and atomoxetine, including nine methylphenidate formulations, five amphetamine formulations, and one norepinephrine reuptake inhibitor, now indicated for treatment of attention-deficit hyperactivity disorder (ADHD). Six of the nine methylphenidate formulations, three of the five compounds, and the norepinephrine reuptake inhibitor are long-acting, potentially once-daily agents. Data on treatment of common adverse events are described, and data on investigational treatments of ADHD are reviewed.
Prince
Jefferson B
JB
Department of Child Psychiatry, Massachusetts General Hospital, Harvard Medical School, 6900 Yawkey Building, 15 Parkman Street, Boston, MA 02114, USA. jprince@partners.org
D000293:Adolescent; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000145:classification*; D002648:Child; D003692:Delayed-Action Preparations; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000627:therapeutic use*; D009638:Norepinephrine / Q000037:antagonists & inhibitors*; D011437:Propylamines / Q000494:pharmacology* / Q000627:therapeutic use*
D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride; D009638:Norepinephrine